Annexon (ANNX) shares lost ~58% on Thursday after it geographic atrophy candidate ANX007 failed in a Phase 2 trial and JPMorgan downgraded the stock. Read more here.
Operator: Good afternoon, and welcome to the Ultragenyx First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.